Empty pipelines drive deal valuations in pharmaceuticals sector, say IMAP
A drought of domestic growth opportunities and new products is inflating valuations for R&D companies as deal values rocket by 75%, according to corporate finance experts at international M&A network, IMAP, announcing the launch of IMAP’s 2012 Global Pharma and Biotech Report, which analyses the latest trends and M&A activity in pharmaceutical and biotechnology sector.
Although deal numbers within the global pharmaceutical and biotechnology sector fell from 548 to 504 transactions between 2010 and 2011, deal values rose sharply by 75% to $90 billion during the same period. The larger end of the market was more active with deals in the $100 million to $1 billion range increasing from 31 to 81.
Promising research assets fuel valuations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze